Trafford Publishing: Conquering Macular Degeneration: The Latest Breakthroughs and Treatments

Here is the full reference card for this book...

If you'd rather place an order by talking to one of our cheerful order desk clerks, please call 1-888-232-4444 (USA and Canada only) or 250-383-6864. From Europe, ring our UK order desk clerk at local rate number 0845 230 9601 (UK only) or 44 (0)1865 722 113.

Conquering Macular Degeneration: The Latest Breakthroughs and Treatments

by Edward L. Paul, Jr., O.D., Ph.D.

95 pages; quality trade paperback (softcover); catalogue #02-0605; ISBN 1-55369-792-8; US$14.95, C$23.00, EUR15.00, £10.40

Macular degeneration is the leading cause of blindness in North America and affects as many as 15 million people. Getting old and going blind is not your only option! What most eye doctors are telling their patients is that there is no treatment for this disease... and that simply isn't true.

Read more!

about the book about the author sample excerpts or Table of Contents catalogue info

About the Book

Macular degenertaion is the leading cause of blindness for those over the age of 65 and affects as many as 15 million North Americans. That number is projected to grow to an epidemic 30 million by 2010. "Getting old and going blind is not your only option! What most eye doctors are telling their patients is that there is no treatment for this disease... and that simply isn't true." These controversial words come from one of the nation's leading authorities on eye disease, Dr. Edward L. Paul, Jr.
This ground breaking book discloses the latest breakthroughs and treatments for macular degeneration. Debunking the myths that surround this blinding disease, Dr. Paul disucusses new research evolving in the field of nutrition as well as cutting edge therapies in electro medicine such as MCS™ Therapy. "MCS™ is a new safe, nonsurgical, inexpensive and painless treatment that is helping over 75% of the patients treated," says Dr. Paul.
In this book, you'll learn:

How to dramatically improve your vision in 4 days.
Why your eye doctor doesn't know about these new therapies.
How inexpensive nutritional supplements may save your eyesight.
How taking one simple action will improve your chances of recovery by 350%.

Conquering macular degeneration is finally achievable and there is now hope where previously there was none. Dr. Paul's book uncovers secrets that will truly become the medicine of the millennium.

About the Author

Dr. Edward L. Paul, Jr. is widely regarded as one of the world's leading authorities on nutrition and eye disease. He was selected as one of "America's Top Optometrists" in 2002 by the Consumer's Research Council of America. He has been in private practice for 17 years and has treated more than 50,000 patients.
Dr. Paul graduated from the Southern College of Optometry in Memphis, TN and completed his internship training at Womack Army Hospital at Fort Bragg in Fayetteville, NC and St. Luke's Eye Institute in Tarpon Springs, FL. In addition to his doctorate in optometry, he also holds a Ph.D. in nutrition. He was a contributing author of the book "Alternative Cures" and serves as a consultant to Rodale, publishers of PREVENTION magazine. Dr. Paul is an accomplished writer, educator, and lecturer. Dr. Paul is a Visiting Professor of Opthalmology at St. Luke's University School of Medicine.
His charitable contributions include service as a medical missionary for the needy in Nicaragua, Belize, and Haiti. He is a Diplomat of the American Board of Disability and a Fellow of the Academy of Learning and Developmental Disorders.

Sample Excerpt - Chapter Three

Micro Current Stimulation (MCS*) Therapy
Micro Current Stimulation (MCS*) Therapy is perhaps the most promising treatment currently being investigated for macular degeneration. It is a non surgical procedure which involves stimulating the macula and nerve fibers with a very low intensity current using a FDA approved battery operated device. The current is delivered at different electrical frequencies through electrodes applied over closed eye-lids. The treatment causes no discomfort or pain and is administered twice each day. While a very effective form of treatment, MCS* Therapy is not a cure for macular degeneration and must be continued for the life of the patient. Overall, no side effects or adverse reactions related to this procedure have been observed. Micro Current Stimulation technology has advanced to the point where individuals can learn to apply their own Micro Current Stimulation therapy with a home unit. In many cases, a patient undergoing MCS* Therapy will experience an improvement in vision in as little as four days. For individuals with a more severe form of the disease it may take several months.
Human cells are not unlike batteries. They sometimes have low energy stores or are unable to hold energy. Micro Current Stimulation Therapy provides the cells with the "energy" it needs, similar to recharging a battery. Studies have also shown that MCS* Therapy increases microcirculatory blood flow, increases ATP concentrations and stimulates amino acid and nutrient concentrations into cells.
When we were discussing Ginkgo Biloba Extract in the previous chapter, we touched on the fact that every living cell in the body has an electrical charge. It is theorized that part of what causes macular degeneration is a loss of the energy source in the cell, or loss of the electrical charge. Just like a flashlight will not work without a charged battery, the photoreceptors in the retina will not function without an energy source. MCS* Therapy is believed to increase the energy source within the cell.
The Macular Degeneration Foundation determined in preliminary preclinical trials by pioneering ophthalmologists and researchers that micro current stimulation therapy can improve visual acuity, sharpness and color perception in 68 percent of patients with dry macular degeneration and 58 percent of those with the wet form. Reports from Russia suggest similar benefits.
A study published by Dr. Merrell J. Allen and Dr. Leland D. Michael entitled Nutritional Supplementation, Electrical Stimulation and Age Related Macular Degeneration showed that 60 percent of patients showed an improvement in visual acuity following a combination of micro current stimulation therapy and nutritional supplementation.
Drs. Grace Halloran and August L. Reader studied thirty individuals diagnosed with typically untreatable eye diseases including macular degeneration, retinitis pigmentosa, CMV-retinitis, and diabetic retinopathy. The patients were treated with a combination of micro current stimulation therapy and nutritional supplementation. Overall results showed remarkable increase in visual function in visual acuity in most and clearly established the safety of the combination of MCS therapy and nutritional supplementation.
Frequently Asked Questions About MCS* Therapy
How Does MCS* Therapy Work?
In general, the electrical current gently wakes up the cells from sleep and stimu-lates the healing process. Simply put, cells are like batteries. When the energy level runs low or runs out, the light goes out. MCS Therapy replaces the electrical charge within the cells of the eye to promote healing and regeneration.
The second way the therapy works is to boost the cells' ability to rid themselves of waste products. A cell with "stuck" waste products becomes a dead cell and interferes with cellular communication throughout the area where it is located. Cells need to take in nutrients and eliminate waste like all other living organisms. The energy supplied by MCS Therapy stimulates the cells to become vital and less sluggish.
The third way MCS Therapy works is by increasing blood supply to the area stimulated. By increasing blood flow to the area cells and tissues are nourished, refreshed and oxygenation is increased.
Is MCS* Therapy Safe?
No side effects or adverse outcomes related to this treatment have been seen. No increase in the conversion to the wet form of AMD has been seen in those who have been treated.
What Is The Treatment Like?
MCS* Therapy can be administered in a doctors office or through a home treatment unit. Even if you start your therapy in a doctors office, continued therapy with a home treatment unit is necessary in order to retain any vision improvement and to keep AMD from getting worse.
After learning how to self-administer treatment, you will perform treatment in the convenience of your home with the home treatment unit. This is easy to learn and apply. Once starting with the treatments you will need to continue with treatments twice daily. Each treatment takes 6 - 12 minutes. Those who have discontinued therapy have had their vision deteriorate.
How Much Improvement In Vision Can I Expect With MCS* Therapy?
The results have been remarkable, with over 68% of the people treated with Dry AMD showing statistically significant improvement in one or both eyes and 58% of the people with Wet AMD showing improve-ment. 52% of patients experience an im-provement of two or more lines as measured with the standard Snellen visual acuity chart.
Why Doesn't My Optometrist or Ophthal-mologist Know About MCS* Therapy?
As we discussed in the Introduction of this book, the majority of eye doctors in practice today were told that macular degeneration was an untreatable disease and that nothing could be done to restore a damaged retina to a healthier state. It is also interesting to note that most of the doctors in practice today were also trained to believe that nutritional supplements were a waste of time and money. After 20 years, they have finally admitted they were wrong regarding vitamins. Medicine, as a profession, is slow to change or admit its mistakes.
Micro current stimulation therapy is currently viewed by most doctors the way vitamin supplements were viewed 20 years ago, as an "unconventional" therapy. While small studies have been published in the literature showing the effectiveness of MCS* Therapy, admittedly, there have not been any large-scale scientific studies published in the traditional journals. These large-scale studies are what most doctors depend on to guide them in their recommendations to patients.
Several large scale studies are either underway or are currently being developed and they should prove MCS* Therapy's effectiveness once and for all. However, it will take 3 - 5 years and millions of dollars in research funds to complete the studies. In the interim, there is no reason that this option should be withheld from patients. The early reports are showing positive results in 65 to 90 percent of patients treated, there are no known side effects or contraindications, the treatment is relatively inexpensive, and there is no alternative treatment. Why should a patient with an otherwise "incurable" disease not try this option?

Catalogue Information